Agilent Technologies (NYSE:A) Price Target Raised to $196.00

Agilent Technologies (NYSE:A) had its price target lifted by TD Cowen from $180.00 to $196.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other analysts also recently commented on the company. UBS Group started coverage on Agilent Technologies in a research report on Wednesday, September 9th. They set a “neutral” rating and a $165.00 target price on the stock. Sanford C. Bernstein upped their target price on Agilent Technologies from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Jefferies Financial Group started coverage on Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price target for the company. Barclays lifted their price target on Agilent Technologies from $175.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings upgraded shares of Agilent Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.65.

Agilent Technologies Trading Up 0.9%

Shares of Agilent Technologies stock opened at $175.54 on Tuesday. Agilent Technologies has a 12-month low of $108.35 and a 12-month high of $177.05. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50. The stock has a market cap of $49.49 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 2.65 and a beta of 1.21. The company has a 50-day moving average of $158.46 and a two-hundred day moving average of $137.30.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period last year, the firm earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts anticipate that Agilent Technologies will post 6.20 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th will be given a dividend of $0.2550 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is currently 20.08%.

Insiders Place Their Bets

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the sale, the director directly owned 4,924 shares of the company’s stock, valued at $745,395.12. This trade represents a 11.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of A. V Square Quantitative Management LLC boosted its position in Agilent Technologies by 5.4% during the third quarter. V Square Quantitative Management LLC now owns 7,998 shares of the medical research company’s stock worth $1,378,000 after acquiring an additional 408 shares during the last quarter. Barlow Wealth Partners LLC purchased a new stake in Agilent Technologies in the 3rd quarter worth approximately $210,000. Assenagon Asset Management S.A. raised its holdings in Agilent Technologies by 235.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 35,114 shares of the medical research company’s stock valued at $6,050,000 after acquiring an additional 24,660 shares during the last quarter. WealthPlan Investment Management LLC acquired a new position in Agilent Technologies in the 3rd quarter valued at $245,000. Finally, Mather Group LLC. lifted its stake in shares of Agilent Technologies by 8.0% during the 3rd quarter. Mather Group LLC. now owns 2,907 shares of the medical research company’s stock worth $501,000 after purchasing an additional 215 shares during the period.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analyst price-target support: Morgan Stanley forecast meaningful appreciation for Agilent shares, while TD Cowen raised its price target. The revisions reinforce positive Wall Street sentiment and suggest analysts see additional upside despite the stock’s recent gains. Morgan Stanley Forecasts Strong Price Appreciation for Agilent Technologies Stock Agilent Technologies Stock Gets Price Target Bump from TD Cowen
• Positive Sentiment: Proscia acquisition expands AI capabilities: Agilent agreed to acquire pathology-software company Proscia for $240 million upfront, with the total consideration potentially reaching $270 million through milestones. The deal would strengthen Agilent’s position in AI-enabled digital pathology and scientific intelligence, adding a potentially faster-growing software component to its tools and diagnostics portfolio. Agilent Technologies to Acquire Proscia
• Positive Sentiment: Favorable market backdrop: A new industry report projects the global metabolomics market will expand at a 17.3% compound annual growth rate through 2030. Agilent is identified as one of the companies positioned to benefit as laboratories adopt AI-assisted diagnostics and advanced analytical technologies. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, which could improve access to regional demand and support longer-term growth. However, execution, regulatory and geopolitical risks remain considerations for investors. Agilent to Expand Capabilities in China
• Negative Sentiment: Acquisition costs and integration risk: The Proscia transaction requires substantial capital and may create integration and milestone-payment risks before it contributes materially to earnings. With Agilent already trading at a premium valuation, investors may scrutinize the deal’s execution and return on investment.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.